Duvie (lobeglitazone) / Chong Kun Dang 
Welcome,         Profile    Billing    Logout  
 12 Diseases   7 Trials   7 Trials   180 News 


«123»
  • ||||||||||  Duvie (lobeglitazone) / Chong Kun Dang, CKD-393 / Chong Kun Dang
    Trial completion, Trial completion date:  A Study to Investigate the PK and Safety of CKD-393 (clinicaltrials.gov) -  Aug 2, 2021   
    P1,  N=26, Completed, 
    Not yet recruiting --> Completed Not yet recruiting --> Completed | Trial completion date: Jul 2021 --> Apr 2021
  • ||||||||||  Duvie (lobeglitazone) / Chong Kun Dang
    Trial completion date, Trial primary completion date:  Comparison of Lobeglitazone With Pioglitazone as Initial Triple Therapy for Diabetes Management (clinicaltrials.gov) -  Apr 22, 2021   
    P4,  N=190, Recruiting, 
    Trial primary completion date: Dec 2020 --> Dec 2021 Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Oct 2020 --> Dec 2021
  • ||||||||||  Duvie (lobeglitazone) / Chong Kun Dang
    Journal:  The antidiabetic drug lobeglitazone has the potential to inhibit PTP1B activity. (Pubmed Central) -  Mar 2, 2021   
    Surprisingly, lobeglitazone led to moderate inhibition on PTP1B (IC 42.8 ± 3.8 µM) activity and to a non-competitive reversible mechanism of action. As lobeglitazone inhibits PTP1B activity in vitro, we speculate that it could also target PTP1B signalling pathway in vivo and thus contribute to potentiate its antidiabetic effects.
  • ||||||||||  Duvie (lobeglitazone) / Chong Kun Dang, CKD-393 / Chong Kun Dang
    New P1 trial:  A Study to Investigate the PK and Safety of CKD-393 (clinicaltrials.gov) -  Feb 23, 2021   
    P1,  N=24, Not yet recruiting, 
  • ||||||||||  Duvie (lobeglitazone) / Chong Kun Dang, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca, Januvia (sitagliptin) / Merck (MSD)
    Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy:  Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy (clinicaltrials.gov) -  Apr 8, 2020   
    P4,  N=78, Active, not recruiting, 
    This study suggests that CKD-395 0.5/1000 mg exhibits similar exposure and absorption rates to coadministration of single agents and is well tolerated under both fasted and fed conditions. Recruiting --> Active, not recruiting | Trial completion date: Dec 2019 --> Dec 2021 | Trial primary completion date: Nov 2019 --> Dec 2020
  • ||||||||||  Duvie (lobeglitazone) / Chong Kun Dang, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca, Januvia (sitagliptin) / Merck (MSD)
    Trial completion date, Trial primary completion date, Combination therapy:  Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy (clinicaltrials.gov) -  Mar 15, 2019   
    P4,  N=78, Recruiting, 
    Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Oct 2018 --> Oct 2020 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Nov 2018 --> Nov 2019
  • ||||||||||  Duvie (lobeglitazone) / Chong Kun Dang
    Trial completion:  Clinical Trial to Evaluate the Drug Drug Interaction of CKD-501 and D308 (clinicaltrials.gov) -  Nov 19, 2018   
    P1,  N=41, Completed, 
    Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Nov 2018 --> Nov 2019 Recruiting --> Completed
  • ||||||||||  Duvie (lobeglitazone) / Chong Kun Dang
    Trial completion, Trial completion date, Trial primary completion date:  Therapeutic Efficacy of Triple Combination in Drug-na (clinicaltrials.gov) -  Sep 17, 2018   
    P4,  N=200, Completed, 
    Recruiting --> Completed Recruiting --> Completed | Trial completion date: Dec 2017 --> Sep 2018 | Trial primary completion date: Dec 2017 --> Sep 2018
  • ||||||||||  Duvie (lobeglitazone) / Chong Kun Dang, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca, Januvia (sitagliptin) / Merck (MSD)
    Trial primary completion date, Combination therapy:  Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy (clinicaltrials.gov) -  Sep 11, 2018   
    P4,  N=78, Recruiting, 
    Recruiting --> Completed | Trial completion date: Dec 2017 --> Sep 2018 | Trial primary completion date: Dec 2017 --> Sep 2018 Trial primary completion date: Aug 2018 --> Nov 2018
  • ||||||||||  Duvie (lobeglitazone) / Chong Kun Dang
    Trial completion date, Trial primary completion date:  Comparison of Lobeglitazone With Pioglitazone as Initial Triple Therapy for Diabetes Management (clinicaltrials.gov) -  Sep 11, 2018   
    P4,  N=190, Recruiting, 
    Trial primary completion date: Aug 2018 --> Nov 2018 Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Oct 2018
  • ||||||||||  Duvie (lobeglitazone) / Chong Kun Dang
    Enrollment open:  Clinical Trial to Evaluate the Drug Drug Interaction of CKD-501 and D308 (clinicaltrials.gov) -  Aug 7, 2018   
    P1,  N=40, Recruiting, 
    Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Oct 2018 Not yet recruiting --> Recruiting
  • ||||||||||  Duvie (lobeglitazone) / Chong Kun Dang
    Enrollment change:  Therapeutic Efficacy of Triple Combination in Drug-na (clinicaltrials.gov) -  Oct 9, 2017   
    P4,  N=200, Recruiting, 
    Trial primary completion date: Jan 2018 --> Aug 2018 N=120 --> 200
  • ||||||||||  Duvie (lobeglitazone) / Chong Kun Dang
    Trial primary completion date:  Therapeutic Efficacy of Triple Combination in Drug-na (clinicaltrials.gov) -  Aug 11, 2017   
    P4,  N=120, Recruiting, 
    Trial primary completion date: Jun 2017 --> Dec 2017 Trial primary completion date: Apr 2017 --> Dec 2017
  • ||||||||||  Duvie (lobeglitazone) / Chong Kun Dang
    Trial primary completion date:  Therapeutic Efficacy of Triple Combination in Drug-na (clinicaltrials.gov) -  Feb 28, 2017   
    P4,  N=120, Recruiting, 
    Trial primary completion date: Dec 2016 --> Mar 2017 Trial primary completion date: Dec 2016 --> Apr 2017